Legend: Palais des congrès de Montréal = CC, Le Westin Montréal = W, Intercontinental Montréal = I
A * preceding a session name means that the session is an applied session.
A ! preceding a session name means that the session reflects the JSM meeting theme.
A * preceding a session name means that the session is an applied session.
A ! preceding a session name means that the session reflects the JSM meeting theme.
Activity Details
|
|
Tweet | ||
| 228 * | Mon, 8/5/2013, 2:00 PM - 3:50 PM | CC-516c | |
| Future Evolution of Data Monitoring Committees — Topic Contributed Papers | |||
| Biopharmaceutical Section , Biometrics Section | |||
| Organizer(s): Zoran Antonijevic, Cytel | |||
| Chair(s): Christy J. Chuang-Stein, Pfizer | |||
| 2:05 PM | The Role of the Data-Monitoring Committee: The Past and the Present in Preparation for the Future — John Loewy, Dataforethought | ||
| 2:25 PM | General Considerations for Data Monitoring of Adaptive Trials — Zoran Antonijevic, Cytel | ||
| 2:45 PM | Communication, Confidentiality, and Oversight Issues for DMCs in Adaptive Trials — Paul Gallo, Novartis | ||
| 3:05 PM | Discussant: Matilde Sanchez, Arena Pharmaceuticals; Inc | ||
| 3:25 PM | Discussant: Kerry Barker, Pfizer Inc. | ||
| 3:45 PM | Floor Discussion | ||
2013 JSM Online Program Home
For information, contact jsm@amstat.org or phone (888) 231-3473.
If you have questions about the Continuing Education program, please contact the Education Department.
The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.
Copyright © American Statistical Association.